The pressing questions in multiple sclerosis Care in the era of COVID-19.

J Neurol Sci

Multiple Sclerosis and Neuroimmunology Program, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA; VA Multiple Sclerosis Center of Excellence, Cleveland VA Medical Center, Cleveland, OH, USA.

Published: September 2020

• MS patients should continue their disease modifying therapy during the pandemic. • Newly diagnosed patients should start disease modifying therapy without delay. • The effect on COVID-19 infection and future vaccination should be considered. • Agents that cause prolonged non-selective lymphopenia are not preferred. • Only severe relapses should be treated preferably with oral steroids at home.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308765PMC
http://dx.doi.org/10.1016/j.jns.2020.117005DOI Listing

Publication Analysis

Top Keywords

disease modifying
8
modifying therapy
8
5
pressing questions
4
questions multiple
4
multiple sclerosis
4
sclerosis care
4
care era
4
era covid-19
4
covid-19 •
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!